Literature DB >> 32015989

Antithrombotic therapy after coronary artery stenting in atrial fibrillation: dual therapy encompassing NOAC plus P2Y12 inhibitor is ready for prime time!

Andreas Goette1.   

Abstract

Entities:  

Year:  2019        PMID： 32015989      PMCID： PMC6976507          DOI： 10.21037/atm.2019.12.33

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  14 in total

1.  Stent Thrombosis in Patients With Atrial Fibrillation Undergoing Coronary Stenting in the AUGUSTUS Trial.

Authors:  Renato D Lopes; Sergio Leonardi; Daniel M Wojdyla; Amit N Vora; Laine Thomas; Robert F Storey; Dragos Vinereanu; Christopher B Granger; Shaun G Goodman; Ronald Aronson; Stephan Windecker; Holger Thiele; Marco Valgimigli; Roxana Mehran; John H Alexander
Journal:  Circulation       Date:  2019-11-11       Impact factor: 29.690

2.  Evaluation of the safety and efficacy of an edoxaban-based antithrombotic regimen in patients with atrial fibrillation following successful percutaneous coronary intervention (PCI) with stent placement: Rationale and design of the ENTRUST-AF PCI trial.

Authors:  Pascal Vranckx; Thorsten Lewalter; Marco Valgimigli; Jan G Tijssen; Paul-Egbert Reimitz; Lars Eckardt; Hans-Joachim Lanz; Wolfgang Zierhut; Rüdiger Smolnik; Andreas Goette
Journal:  Am Heart J       Date:  2017-10-23       Impact factor: 4.749

3.  EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: definition, characterization, and clinical implication.

Authors:  Andreas Goette; Jonathan M Kalman; Luis Aguinaga; Joseph Akar; Jose Angel Cabrera; Shih Ann Chen; Sumeet S Chugh; Domenico Corradi; Andre D'Avila; Dobromir Dobrev; Guilherme Fenelon; Mario Gonzalez; Stephane N Hatem; Robert Helm; Gerhard Hindricks; Siew Yen Ho; Brian Hoit; Jose Jalife; Young-Hoon Kim; Gregory Y H Lip; Chang-Sheng Ma; Gregory M Marcus; Katherine Murray; Akihiko Nogami; Prashanthan Sanders; William Uribe; David R Van Wagoner; Stanley Nattel
Journal:  Europace       Date:  2016-07-08       Impact factor: 5.214

4.  Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation.

Authors:  Christopher P Cannon; Deepak L Bhatt; Jonas Oldgren; Gregory Y H Lip; Stephen G Ellis; Takeshi Kimura; Michael Maeng; Bela Merkely; Uwe Zeymer; Savion Gropper; Matias Nordaby; Eva Kleine; Ruth Harper; Jenny Manassie; James L Januzzi; Jurrien M Ten Berg; P Gabriel Steg; Stefan H Hohnloser
Journal:  N Engl J Med       Date:  2017-08-27       Impact factor: 91.245

5.  Safety and Efficacy of Antithrombotic Strategies in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Network Meta-analysis of Randomized Controlled Trials.

Authors:  Renato D Lopes; Hwanhee Hong; Ralf E Harskamp; Deepak L Bhatt; Roxana Mehran; Christopher P Cannon; Christopher B Granger; Freek W A Verheugt; Jianghao Li; Jurriën M Ten Berg; Nikolaus Sarafoff; C Michael Gibson; John H Alexander
Journal:  JAMA Cardiol       Date:  2019-08-01       Impact factor: 14.676

6.  Atrial fibrillation down-regulates renal neutral endopeptidase expression and induces profibrotic pathways in the kidney.

Authors:  Alicja Bukowska; Uwe Lendeckel; Alexander Krohn; Gerburg Keilhoff; Sara ten Have; Klaus Hinrich Neumann; Andreas Goette
Journal:  Europace       Date:  2008-08-08       Impact factor: 5.214

7.  Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial.

Authors:  Pascal Vranckx; Marco Valgimigli; Lars Eckardt; Jan Tijssen; Thorsten Lewalter; Giuseppe Gargiulo; Valerii Batushkin; Gianluca Campo; Zoreslava Lysak; Igor Vakaliuk; Krzysztof Milewski; Petra Laeis; Paul-Egbert Reimitz; Rüdiger Smolnik; Wolfgang Zierhut; Andreas Goette
Journal:  Lancet       Date:  2019-09-03       Impact factor: 79.321

8.  Effect of atrial fibrillation on hematopoietic progenitor cells: a novel pathophysiological role of the atrial natriuretic peptide?

Authors:  Andreas Goette; Kathleen Jentsch-Ullrich; Uwe Lendeckel; Christoph Röcken; Mahmood Agbaria; Angelo Auricchio; Martin Mohren; Astrid Franke; Helmut U Klein
Journal:  Circulation       Date:  2003-11-10       Impact factor: 29.690

9.  Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials.

Authors:  Giuseppe Gargiulo; Andreas Goette; Jan Tijssen; Lars Eckardt; Thorsten Lewalter; Pascal Vranckx; Marco Valgimigli
Journal:  Eur Heart J       Date:  2019-12-07       Impact factor: 29.983

10.  Determinants of left atrium thrombi in scheduled cardioversion: an ENSURE-AF study analysis.

Authors:  Jose L Merino; Gregory Y H Lip; Hein Heidbuchel; Aron-Ariel Cohen; Raffaele De Caterina; Joris R de Groot; Michael D Ezekowitz; Jean-Yves Le Heuzey; Sakis Themistoclakis; James Jin; Michael Melino; Shannon M Winters; Béla Merkely; Andreas Goette
Journal:  Europace       Date:  2019-11-01       Impact factor: 5.214
View more
  2 in total

1.  Platelet microRNA-15b protects against high platelet reactivity in patients undergoing percutaneous coronary intervention through Bcl-2-mediated platelet apoptosis.

Authors:  Jinghan Wang; Yi Yao; Jiahui Zhang; Xiaofang Tang; Xianmin Meng; Miao Wang; Lei Song; Jinqing Yuan
Journal:  Ann Transl Med       Date:  2020-03

2.  Safety and efficacy of double vs. triple antithrombotic therapy in patients with atrial fibrillation with or without acute coronary syndrome undergoing percutaneous coronary intervention: a collaborative meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials.

Authors:  Giuseppe Gargiulo; Christopher P Cannon; Charles Michael Gibson; Andreas Goette; Renato D Lopes; Jonas Oldgren; Serge Korjian; Stephan Windecker; Giovanni Esposito; Pascal Vranckx; Marco Valgimigli
Journal:  Eur Heart J Cardiovasc Pharmacother       Date:  2021-04-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.